GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
2.100
+0.150 (7.69%)
May 2, 2025, 4:00 PM EDT - Market closed
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,529,500
Market Cap
1.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 3 | 300.00% |
| Dec 31, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GRI News
- 17 days ago - GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference - GlobeNewsWire
- 4 weeks ago - GRI Bio Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday? - Benzinga
- 4 weeks ago - GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewsWire
- 6 weeks ago - GRI Bio Participates in a Virtual Investor CEO Connect Segment - GlobeNewsWire
- 6 weeks ago - GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
- 7 weeks ago - GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire